Novo Nordisk A/S (NVO) Stock Grade

About Novo Nordisk A/S's fundamentals

Novo Nordisk is a large-cap pharmaceutical company with a market capitalization of $203.8 billion, trading at a P/E ratio of 14.1 while generating 33.1% net margins—indicating strong profitability relative to sales. The company demonstrated modest revenue growth of 6.4% year-over-year and delivered an exceptional return on equity of 52.8%, reflecting highly efficient use of shareholder capital. With a dividend yield of 3.6%, the company returns cash to shareholders while maintaining substantial earnings reinvestment capacity.